Analysts have modestly increased their price target for TG Therapeutics, raising it from approximately $43.57 to $44.29. This adjustment is due to optimism about multi-year sales growth for Briumvi and updated post-earnings forecasts.

Analyst Commentary

Following the recent earnings update and price target revisions, analysts have shared several perspectives regarding TG Therapeutics' outlook and valuation.

Bullish Takeaways

• Bullish analysts believe TG Therapeutics is positioned for significant multi-year sales growth, particularly driven by Briumvi’s performance in the U.S. market.
• Expectations are that Briumvi could surpass $1 billion in annual revenue within the next few years. This would indicate strong market adoption and broad patient demand.
• The recent price target increases reflect confidence in upward momentum and improved financial forecasts following earnings results.
• Some analysts see the recent pullback in shares after earnings as a potential buying opportunity and anticipate the company can execute on its commercial strategies.

Bearish Takeaways

• Bearish analysts express caution regarding the company’s ability to sustain robust sales growth in a competitive therapeutic landscape.
• There remain questions about TG Therapeutics’ execution risks as it looks to expand Briumvi’s footprint and reach revenue milestones.
• Analysts are watchful of how quickly the company can convert optimistic projections into tangible financial results amid market volatility.

What's in the News

• TG Therapeutics raised its 2025 global revenue target from $585 million to approximately $600 million (Corporate Guidance).
• Enrollment has been completed in the Phase 3 ENHANCE trial evaluating a consolidated dosing schedule for IV BRIUMVI in patients with relapsing forms of multiple sclerosis (Product-Related Announcements).
• Updated six-year data from the ULTIMATE I & II Phase 3 trials support long-term efficacy and safety of BRIUMVI, with positive real-world and clinical trial alignment (Product-Related Announcements).
• The company commenced enrollment for a Phase 3 trial of subcutaneous BRIUMVI in relapsing forms of multiple sclerosis (Product-Related Announcements).
• TG Therapeutics announced completion of its $100 million share repurchase program, with a total of 3,500,000 shares bought back (Buyback Transaction Announcements).

Valuation Changes

• The consensus analyst price target has increased slightly from $43.57 to $44.29.
• The discount rate has decreased marginally from 6.91% to 6.89%.
• Revenue growth estimates have fallen from 39.80% to 37.75%.
• Net profit margin projections have declined notably from 35.38% to 28.00%.
• Future P/E ratio forecasts have risen from 18.56x to 20.98x.